ICI monotherapy, PD-1 inhibitors, or CTLA-4 inhibitors also had very significant associations with vitiligo, with RORs of 32.43 (26.85–39.18) and 29.23 (19.48–43.86), respectively. This evidence concerns the gene CTLA4 and vitiligo.